Sensitivity of Proliferating Cultured Murine Pancreatic Tumor Cells to Selected Antitumor Agents23
- 1 November 1986
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 77 (5) , 1163-1169
- https://doi.org/10.1093/jnci/77.5.1163
Abstract
Cultured cell populations derived from the refractory murine pancreatic ductal adenocarcinoma (Panc 02) were propagated in modified Eagle's minimal essential medium supplemented with 20% fetal bovine serum and had a doubling time of 19.1±4.7 hours (mean ± SD). The Panc 02 cell populations were tested against 8 antitumor agents and exhibited different sensitivities to the agents in a 24-hour growth-inhibition assay. The concentration that inhibits the growth of the test culture by 50% relative to the growth of the control culture (IC50) in micromolars was determined for each agent. The IC50 values were: doxorubicin (ADR), 0.055; vincristine (VCR), 0.042; 5-fluorouracil, 1.92; cytarabine, 5.35; melphalan, 10.5; cisplatin, 17.0; carmustine (BCNU), 46.2; and lomustine (CCNU), 52.6. These IC50's were estimated to be pharmacologically attainable concentrations in mice. On a micromolar basis, the Panc 02 cells were the most sensitive to VCR and ADR and the least sensitive to BCNU and CCNU. By the use of a colony-forming assay and a 24-hour exposure period and the evaluation of each agent at 1/3 × IC50, 1 × IC50, and 3 × IC50, the degree of cell killing was greater than predicted on the basis of the IC50's determined in the growth-inhibition assay. The use of a 1-hour exposure period resulted in a very minimal reduction in viability of the cell populations except for BCNU and CCNU. It was concluded that the degree of cell killing was a function of drug concentration and time of exposure and that the pancreatic tumor in vivo should be sensitive to these agents, provided effective concentrations and exposure periods can be achieved at the tumor target sites.Keywords
This publication has 10 references indexed in Scilit:
- Chemotherapy for advanced pancreatic cancer.A comparison of 5-fluorouracil, adriamycin, and mitomycin (fam) with 5-fluorouracil, streptozotocin, and mitomycin (fsm)Cancer, 1986
- Sensitivity of cultured human pancreatic carcinoma cells to dihydroxyanthracenedioneInternational Journal of Cancer, 1984
- INDUCTION AND CHEMOTHERAPEUTIC RESPONSE OF 2 TRANSPLANTABLE DUCTAL ADENOCARCINOMAS OF THE PANCREAS IN C57BL-6 MICE1984
- 5-Fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreasCancer, 1980
- Viability of Cultured Lewis Lung Cell Populations Exposed to -Retinoic AcidExperimental Biology and Medicine, 1980
- Cancer of the pancreas. Diagnostic accuracy and survival statisticsCancer, 1978
- Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin-d in advanced measurable pancreatic carcinoma.A gastrointestinal tumor study group reportCancer, 1978
- Phase II trial of streptozotocin, mitomycin-C and 5-fluorouracil (SMF) in the treatment of advanced pancreatic cancerCancer, 1978
- Murine Colon Adenocarcinomas: Methods for Selective Culture In Vitro 2JNCI Journal of the National Cancer Institute, 1976
- PHASE-2 STUDY OF METHYL-CCNU IN TREATMENT OF ADVANCED PANCREATIC CARCINOMA1976